&lt;p&gt;Altered circulating levels of adipokine omentin-1 in patients with prostate cancer&lt;/p&gt;

Zhou, Lin; He, Weiming; Wang, Wenjun; Zhou, Dachen

doi:10.2147/ott.s197507

Cited by 15 publications

(14 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings revealed that serum concentrations of omentin were significantly higher in PC subjects than in men with prostate hypertrophy and this phenomenon was independent of BMI and metabolic syndrome. We did not observe any relationships between the Gleason score and omentin levels and this observation correlates with previous findings [14,15]. Additionally, we demonstrated positive correlations between omentin and leptin.…”

Section: Discussionsupporting

confidence: 91%

“…Higher concentrations of omentin were also reported in mesothelioma [21], in gastric cancer [11], and pancreatic cancer [22] and in most of those studies, increased omentin levels were independent of BMI, glucose, and lipid parameters. Increased concentrations of omentin in PC cases were described previously by Zhou et al [14] and in the Turkey population by Uyeturk et al [15]. Higher levels of serum omentin in PC were also observed in the Polish patients [16].…”

Section: Discussionsupporting

confidence: 61%

“…Elevated concentrations of omentin have been described in gastric and colon cancers [11,12]. Several studies have found increased levels of omentin in PC but the underlying mechanism is not fully understood [13][14][15][16]. In this study, we investigated whether serum omentin levels might be a marker for PC.…”

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

Serum Omentin Levels in Patients with Prostate Cancer and Associations with Sex Steroids and Metabolic Syndrome

Borowski¹,

Siemińśka

2020

JCM

View full text Add to dashboard Cite

Mechanisms linking obesity and prostate cancer (PC) include increased insulin signaling, persistent inflammation, and altered adipocytokines secretion. Previous studies indicated that omentin may play a potential role in cancerogenesis of different sites, including the prostate. In this study, we focused on the hormonal and metabolic characteristics of men recruited for prostate biopsy. We evaluated serum concentrations of adipocytokines and sex steroids where concentrations are related to the adiposity: omentin, leptin, testosterone, estradiol, and sex hormone-binding globulin (SHBG). Aim: The aim of the study was to assess the concentration of serum omentin in men with PC. We also investigated relationships between omentin, leptin, sex steroids, SHBG, age, and metabolic syndrome (MS). Methods: Our study was conducted on 72 patients with PC and 65 men with benign prostate hyperplasia (BPH). Both groups were compared for body mass index. Results: Comparing men with PC to subjects with BPH there were significantly higher serum concentrations of omentin, estradiol, and prostate specific antigen (PSA) in the former. Estradiol/testosterone ratio, which is a marker of testosterone to estradiol conversion, was also significantly higher in the PC group. MS was diagnosed in 47 men with PC and in 30 men with BPH, the prevalence was significantly higher in the PC group. When the subjects with PC were subdivided into two subgroups, the serum omentin did not differ between those with MS and without MS. In the overall sample serum, omentin was positively associated with age, SHBG, and leptin. A positive correlation was also found between omentin and estradiol/testosterone ratio, and negatively with testosterone/SHBG ratio. Positive correlations were noted between age and SHBG, PSA and estradiol/testosterone ratio. In our study, a drop of total testosterone and testosterone/SHBG ratio, due to age, was also demonstrated. Conclusions: In patients with prostate cancer, serum omentin may be a diagnostic indicator. Omentin levels do not correlate with estradiol or testosterone concentrations but they are related to the testosterone/SHBG ratio. Omentin is not associated with an increased likelihood of having metabolic syndrome in men with prostate cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 61%

See 1 more Smart Citation

Serum Omentin Levels in Patients with Prostate Cancer and Associations with Sex Steroids and Metabolic Syndrome

Borowski¹,

Siemińśka

2020

JCM

View full text Add to dashboard Cite

show abstract

“…The interest in the role of ITLN in cancer has been driven by the observation that ITLN1 levels differ between healthy individuals and patients with various types of cancer (7)(8)(9)(10). We recently identified ITLN1 and ITLN2 mRNA as increased in the visceral adipose tissue of gastrointestinal cancer patients and found that local but not circulating ITLN1 protein demonstrated a relationship with cancer cachexia (11).…”

Section: Introductionmentioning

confidence: 99%

The Emerging Role of Intelectin-1 in Cancer

et al. 2022

View full text Add to dashboard Cite

BackgroundIntelectin (ITLN) is an adipokine with two homologs—ITLN1 and ITLN2—that has various physiological functions. Studies analyzing the relationship between ITLN and cancer are focused on ITLN1; the available literature on ITLN2 and cancer is limited. This review aims to evaluate the role of ITLN1 in cancer without imposing any inclusion criteria, to examine pro- and anticancer roles for ITLN1 and to discuss whether the relationship between ITLN and cancer is mediated by obesity.FindingsOverall, ITLN1 level was highly variable in cancer patients but different from healthy individuals. Compared with control groups, patients with gastrointestinal and prostate cancer showed increased concentrations of circulating ITLN1, while patients with gynecological, breast, bladder, and renal cancer had lower ITLN1 levels. Several studies also evaluated tissue and tumor expression of ITLN1. In gastrointestinal cancer, ITLN1 was increased in tumor tissue compared with adjacent healthy tissue and elevated in the visceral adipose tissue of patients compared with controls. Consequently, the high levels of circulating ITLN1 might be determined by the tumor and by the cancer-associated weight loss in gastrointestinal cancer. ITLN1 can activate the phosphoinositide-3-kinase-protein kinase B/Akt (PI3K/Akt) pathway. The improper regulation of this pathway may contribute to a series of cellular events that favor tumor development and progression. Obesity has been linked with an increased risk of developing some cancers. Indeed, low circulating ITLN1 levels may be a marker of the metabolic effects of obesity, rather than obesity per se, and might contribute to a deregulation of the PI3K/Akt pathway.ConclusionsITLN1 could be associated with cancer formation and progression. Since circulating ITLN1 levels are highly variable and differ between cancer types, the local tumor production of ITLN1 could be more relevant in determining malignant behavior. Future research should aim to identify the source of ITLN1 variability, to understand the differences in ITLN1 between distinct tumor types, and to further explore the signaling pathways through which this adipokine influences cancer biology.

show abstract

“…In pancreatic cancer, on the other hand, serum omentin levels were found to be significantly higher in patients compared to healthy controls and have been demonstrated to have a potential diagnostic significance [ 46 ]. Similarly, omentin overexpression was observed in prostate cancer [ 47 ] while it was significantly downregulated in renal cancer patients [ 48 ]. Furthermore, in CRC, omentin plasma levels were found to be positively associated with CRC risk in patients with BMI (body mass index) < 30 whereas, in patients with BMI ≥ 30, it did not show any correlation [ 49 ].…”

Section: Introductionmentioning

confidence: 99%

Role of Omentin in Obesity Paradox in Lung Cancer

Parida

Siddharth

Sharma

2021

Cancers

View full text Add to dashboard Cite

Lung cancer remains the second-most-common cancer worldwide and is associated with the highest number of cancer-related mortality. While tobacco smoking is the most important risk factor for lung cancer, many other lifestyles and occupational factors significantly contribute. Obesity is a growing global health concern and contributes to ~30% cancer-related mortality, but unlike other lifestyle diseases, lung cancer is negatively associated with obesity. We meta-analyzed multiple case-control studies confirming increased survival and better outcomes in overweight and obese lung cancer patients. Tumor heterogeneity analysis showed significant enrichment of adipocytes and preadipocytes in normal lungs compared to lung cancers. Interestingly, one of the understudied adipokine, omentin, was significantly and consistently lower in lung neoplasms compared to normal lungs. Omentin has been examined in relation to osteoarthritis, inflammatory bowel disease, cardiovascular diseases, diabetes, chronic liver disease, psoriasis and some other cancers. Aberrant expression of omentin has been reported in solid tumors; however, little is known about its role in lung cancer. We found omentin to be consistently downregulated in lung cancers, and it exhibited a negative correlation with important transcription factors FOXA1, EN1, FOXC1 and ELK4. We, therefore, suggest that omentin may serve as a prognostic factor in lung cancer and explain the “obesity paradox” in lung cancer.

show abstract

<p>Altered circulating levels of adipokine omentin-1 in patients with prostate cancer</p>

Cited by 15 publications

References 40 publications

Serum Omentin Levels in Patients with Prostate Cancer and Associations with Sex Steroids and Metabolic Syndrome

Serum Omentin Levels in Patients with Prostate Cancer and Associations with Sex Steroids and Metabolic Syndrome

The Emerging Role of Intelectin-1 in Cancer

Role of Omentin in Obesity Paradox in Lung Cancer

Contact Info

Product

Resources

About